Alkermes plc (NASDAQ:ALKS) Stock Analysis: A Look into the Future

Core Viewpoint - Alkermes plc is a biopharmaceutical company focused on innovative medicines for central nervous system disorders and cancer, with a market capitalization of approximately $5.13 billion [1] Financial Performance - Alkermes reported a revenue decline of 10.6% for Q4 2025, totaling $384.55 million compared to the previous year [2] - Despite the revenue decline, Alkermes exceeded the Zacks Consensus Estimate of $379.96 million, resulting in a positive surprise of 1.21% [3] - The company reported earnings per share (EPS) of $0.46 for the quarter, surpassing the consensus estimate of $0.43, marking a 7.8% positive surprise, although down from $1.04 EPS in the same quarter last year [4] Stock Performance - The current stock price of ALKS is $31.04, reflecting a decrease of 7.04% or $2.35, with fluctuations between $30.54 and $32.78 during the trading day [5] - Over the past year, ALKS reached a high of $36.32 and a low of $25.17, with a trading volume of 3,898,927 shares indicating active investor interest [5] Analyst Outlook - Douglas Tsao from H.C. Wainwright set a price target of $43 for Alkermes, indicating a potential upside of 38.53% [2][6]